Loading...
VRDN logo

Viridian Therapeutics, Inc.NasdaqCM:VRDN Stock Report

Market Cap US$2.0b
Share Price
US$17.24
US$33.94
49.2% undervalued intrinsic discount
1Y27.0%
7D2.5%
1D
Portfolio Value
​
View

Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Market Cap: US$2.0b

Viridian Therapeutics (VRDN) Stock Overview

Engages in discovering, developing, and commercializing treatments for serious and rare diseases. More details

VRDN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 87.5% below our estimate of its fair value

Earnings are forecast to grow 60.15% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market


VRDN Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Viridian Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Viridian Therapeutics
Historical stock prices
Current Share PriceUS$17.24
52 Week HighUS$34.29
52 Week LowUS$13.18
Beta0.82
1 Month Change20.31%
3 Month Change-37.17%
1 Year Change27.05%
3 Year Change-27.35%
5 Year Change-4.28%
Change since IPO-90.50%

Recent News & Updates

Analysis Article • Apr 21

Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026

One thing we could say about the analysts on Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) - they aren't optimistic...

Recent updates

Analysis Article • Apr 21

Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026

One thing we could say about the analysts on Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) - they aren't optimistic...
Seeking Alpha • Jan 26

Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade)

Summary Viridian Therapeutics has doubled since June thanks to a string of positive news. VRDN focuses on developing treatments for thyroid eye disease, and analyst firms project huge revenue and earnings growth in the coming years. The company has smartly addressed its long-term funding needs in recent months in anticipation of a coming marketing rollout upon FDA approval. An updated analysis around Viridian Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Nov 22

Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) shares have been powering on, with a gain of...
Analysis Article • Nov 10

Analysts' Revenue Estimates For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Are Surging Higher

Shareholders in Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) may be thrilled to learn that the analysts have just...
Analysis Article • Jul 01

Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 02

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Summary Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive and Thrive-2 trials bolster confidence, with VRDN-001 demonstrating rapid response and consistent efficacy in both active and chronic TED. Financially stable with a cash runway into 2027, Viridian is well-positioned for FDA approval, expected to be a significant catalyst for the stock. Despite Tepezza's market dominance, VRDN-001's superior diplopia resolution and chronic TED data offer potential differentiation and long-term market penetration. Read the full article on Seeking Alpha
Analysis Article • Feb 11

Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Dec 20

Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Viridian Therapeutics fair value estimate is US$14.75 Current...
Analysis Article • Nov 14

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 11

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Seeking Alpha • Sep 10

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Summary Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for THRIVE-2 study, using veligrotug for the treatment of patients with chronic thyroid eye disease, expected end of 2024. It is expected that the 7 major thyroid eye disease markets will reach $4.13 billion by 2034. VRDN-006 and VRDN-008 are two anti-FcRn drugs being developed to treat patients with autoimmune disorders. Read the full article on Seeking Alpha
Seeking Alpha • Jun 12

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Summary Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients are the most important catalysts for the company this year. Matching Tepezza's efficacy and safety would be considered a win, but there is potential for better efficacy and safety. The phase 3 trial design for VRDN-003 addresses concerns about the company needing to conduct a phase 2 trial before going to phase 3. Anti-FcRn pipeline with VRDN-006 and VRDN-008 should get more visibility going forward with non-human primate data of VRDN-008 in 2H 2024 and phase 1 results of VRDN-006 in 2H 2025. Read the full article on Seeking Alpha
Analysis Article • May 28

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Sep 12

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 15

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

Key Insights The projected fair value for Viridian Therapeutics is US$41.58 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Apr 18

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

VRDNUS BiotechsUS Market
7D2.5%1.2%1.0%
1Y27.0%34.9%28.7%

Return vs Industry: VRDN underperformed the US Biotechs industry which returned 34.4% over the past year.

Return vs Market: VRDN matched the US Market which returned 27.1% over the past year.

Price Volatility

Is VRDN's price volatile compared to industry and market?
VRDN volatility
VRDN Average Weekly Movement16.4%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: VRDN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VRDN's weekly volatility has increased from 10% to 16% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010252Steve Mahoneywww.viridiantherapeutics.com

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED.

Viridian Therapeutics, Inc. Fundamentals Summary

How do Viridian Therapeutics's earnings and revenue compare to its market cap?
VRDN fundamental statistics
Market capUS$1.95b
Earnings (TTM)-US$303.27m
Revenue (TTM)US$70.92m
26.8x
P/S Ratio
-6.3x
P/E Ratio

Is VRDN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VRDN income statement (TTM)
RevenueUS$70.92m
Cost of RevenueUS$339.64m
Gross Profit-US$268.72m
Other ExpensesUS$34.55m
Earnings-US$303.27m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-2.75
Gross Margin-378.92%
Net Profit Margin-427.63%
Debt/Equity Ratio7.9%

How did VRDN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/22 05:42
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viridian Therapeutics, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Leah Rush CannBrookline Capital Markets
Jason ButlerCitizens JMP Securities, LLC